IGM Biosciences, Inc. (IGMS)

NASDAQ: IGMS · Real-Time Price · USD
14.64
+0.92 (6.70%)
Oct 8, 2024, 1:39 PM EDT - Market open
6.70%
Market Cap 868.43M
Revenue (ttm) 2.91M
Net Income (ttm) -220.40M
Shares Out 59.32M
EPS (ttm) -3.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 99,420
Open 13.72
Previous Close 13.72
Day's Range 13.72 - 15.04
52-Week Range 3.81 - 22.50
Beta 0.21
Analysts Hold
Price Target 14.00 (-4.37%)
Earnings Date Nov 11, 2024

About IGMS

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 prote... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2019
Employees 224
Stock Exchange NASDAQ
Ticker Symbol IGMS
Full Company Profile

Financial Performance

In 2023, IGM Biosciences's revenue was $2.13 million, an increase of 99.25% compared to the previous year's $1.07 million. Losses were -$246.42 million, 11.4% more than in 2022.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for IGMS stock is "Hold." The 12-month stock price forecast is $14.0, which is a decrease of -4.37% from the latest price.

Price Target
$14.0
(-4.37% downside)
Analyst Consensus: Hold
Stock Forecasts

News

IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay

IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower thei...

7 days ago - Market Watch

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

On Tuesday, IGM Biosciences Inc. IGMS announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for autoimmune diseas...

7 days ago - Benzinga

IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases

The biotechnology company says it will focus only on autoimmune diseases.

7 days ago - Barrons

IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Tuesday.

7 days ago - Benzinga

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus –

7 days ago - GlobeNewsWire

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announce...

27 days ago - GlobeNewsWire

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 –

7 weeks ago - GlobeNewsWire

IGM Biosciences to Present at the Jefferies Healthcare Conference

MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...

4 months ago - GlobeNewsWire

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, C...

5 months ago - GlobeNewsWire

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...

5 months ago - GlobeNewsWire

IGM Biosciences Announces Refocusing of Sanofi Collaboration

Agreement focuses on immunology/inflammation, aligning with Sanofi's ongoing commitment to advancing therapies for patients across multiple inflammatory diseases Agreement focuses on immunology/inflam...

6 months ago - GlobeNewsWire

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announce...

6 months ago - GlobeNewsWire

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announce...

7 months ago - GlobeNewsWire

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

IGM Biosciences, Inc. is conducting phase 1b studies for imvotamab in patients with severe systemic lupus erythematosus and rheumatoid arthritis, with initial results expected in the second half of 20...

8 months ago - Seeking Alpha

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced...

8 months ago - GlobeNewsWire

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced...

9 months ago - GlobeNewsWire

Medivir to present at the Carlsquare Equity Research Investor Day

STOCKHOLM , Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, annou...

10 months ago - PRNewsWire

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All cli...

10 months ago - GlobeNewsWire

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

STOCKHOLM , Dec. 1, 2023 /PRNewswire/ -- Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below was adopted.  The ...

11 months ago - PRNewsWire

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

STOCKHOLM , Nov. 27, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...

11 months ago - PRNewsWire

Medivir to present at the Redeye Life Science Day

STOCKHOLM , Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...

11 months ago - PRNewsWire

Medivir to present at the Erik Penser Bank Company Event

STOCKHOLM , Nov. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...

11 months ago - PRNewsWire

IGM Biosciences Announces Third Quarter 2023 Financial Results

– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Bioscien...

11 months ago - GlobeNewsWire

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

STOCKHOLM , Nov. 13, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...

11 months ago - PRNewsWire

IGM Biosciences to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, toda...

1 year ago - GlobeNewsWire